Biocollection of Patients With ANCA Associated Vasculitis
Study Details
Study Description
Brief Summary
As rare disease, vasculitis affects a small number of patients, the cohorts available in the literature are few and the pathophysiological mechanisms remain to be elucidated. The collection of standardized data within a patientheque as part of a multi-year follow-up will facilitate the study of the characteristics of these diseases. This may, in particular, address the main objective of identifying predictors of relapse, as well as secondary objectives for predictive factors of mortality, infectious, cardiovascular or neoplastic complications that affect the prognosis of vasculitis in order to establish a more appropriate management of the patients concerned.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA) is a group of rare and severe autoimmune diseases, encompassing several entities: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (PMA), and eosinophilic granulomatosis with polyangiitis (GEPA). When untreated, these diseases are fatal in a matter of months. Currently, thanks to the use of corticosteroids and immunosuppressants, this high mortality has greatly decreased and these are now chronic diseases. On the other hand, these patients are at high risk of morbidity, linked to both relapses (occurring in at least 50% of patients) and side effects of treatments. It is therefore essential to be able to define which patients are at risk of relapse and justify long-term immunosuppressive treatment to avoid recurrence of the disease, and conversely which patients have a low risk of relapse and in whom immunosuppressive treatments can be discontinued to limit the risk of side effects. However, so far no predictor or biomarker can accurately assess this risk of relapse.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: ANCA-associated vasculitis - patient library It is a description of ANCA-associated vasculitis patients cohort. All the patients are included in one arm. They will undergo various type of samples. |
Other: Blood samples (80 mL)
Blood samples (80 mL) at inclusion, once a year for 5 years, and if relapse or change of treatment
Other: Fecal samples
Fecal samples at inclusion
Other: Urinary sample (20-40 mL)
Urinary samples at inclusion, once a year for 5 years, and if relapse or change of treatment
Other: Questionnaires
Questionnaires at inclusion, once a year for 5 years, and if relapse or change of treatment
|
Outcome Measures
Primary Outcome Measures
- Relapse-free survival of the disease [Five years after diagnosis]
Relapse-free survival of the disease
Secondary Outcome Measures
- death [Five years after diagnosis]
death
- Age [Five years after diagnosis]
Age
- Sex [Five years after diagnosis]
Sex
- Physician assessment of disease activity [Five years after diagnosis]
Disease activity will be assessed on a scale from 0 to 100, considering the pain and the impact on daily life. A higher score means a worse outcome.
- Patient assessment of disease activity [Five years after diagnosis]
Disease activity will be assessed on a scale from 0 to 100, considering the pain and the impact on daily life. A higher score means a worse outcome.
- BVAS score - Birmingham Vasculitis Activity Score [Five years after diagnosis]
Questionnaire listing 56 symptoms divided into nine organ/systems classes, plus an "other" section. For each item, the assessor evaluates if it is present and attribuable to the active vasculitis or not. A higher score means a worse outcome.
- VDI score - Vasculitis Damage Index [Five years after diagnosis]
This is for recording organ damage that has occurred in patients since the onset of vasculitis, and over 3 months. Record features of active disease using the Birmingham Vasculitis Activity Score (BVAS). A new patient should usually have a VDI score of zero, unless: they have had vasculitis for more than three months of onset of disease. and the damage has developed or become worse since the onset of vasculitis Questionnaire listing 64 symptoms divided into eleven organ/systems classes. For each item, the assessor evaluates if it is present over 3 months and attribuable to the active vasculitis or not. A higher score means a worse outcome.
- Number of patients with refractory character of the Vasculitis [Five years after diagnosis]
Number of patients for whome a secondary decision to intensify immunosupressive treatment in the first year of treatment (increased corticosteroid dosage, introduction of another immunosupressor outside the scheduled at the end of the initial assessment) has been taken.
- HAQ-DI - Health Assessment Questionnaire - Disability Index. [Five years after diagnosis]
Evolution of HAQ-DI during follow-up 8 fields questionnaire (DRESSING & GROOMING, ARISING, EATING, WALKING, HYGENE, REACH, GRIP, Other activites), scaled from 0 to 3, 3 meaning a worse outcome.
- Glucocorticoid toxicity index - Glucocorticoid toxicity index during follow-up Glucocorticoid toxicity index [Five years after diagnosis]
Glucocorticoid toxicity index during follow-up
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Major patients with no upper age limit.
-
Patients assessed as part of the reference centre for rare autoimmune diseases at the CHRU in Brest.
-
Patients for whom a diagnosis of ANCA-associated vasculitis is made by the physician in charge of the patient, according to the definitions of the Chapel-Hill Consensus Conference.
-
Patient affiliated with Social Security
-
Patient who has signed written informed consent
Exclusion Criteria:
-
Minor
-
Patients unable to consent.
-
Patients refusing to participate in research
-
Patient under legal protection (tutelage, curatorship)
-
Pregnant or lactating women
-
Hemoglobin (Hb) < 7g/dL
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHRU de Brest - Service de rhumatologie | Brest | France | 29200 |
Sponsors and Collaborators
- University Hospital, Brest
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 29BRC20.0233